Recent Updates
Recently added Catalysts
DARE Positive Sentiment

DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List

Tuesday, August 18, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Sabrina Martucci Johnson, CEO of Daré Bioscience, has been named to Forbes' 2026 '50 Over 50: Innovation' list. This recognition highlights her leadership as the company advances its multi-product strategy in women's health, focusing on commercialization and clinical development. Daré Bioscience aims to introduce first-in-category innovations.

Market Sentiment Analysis

POSITIVE FACTORS

  • Sabrina Martucci Johnson recognized on Forbes '50 Over 50' list.
  • Daré Bioscience advancing women's health strategy.
  • Company focused on commercialization and innovation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~13 mo
Low dilution risk
Lead asset
Lopinavir/ ritonavir
Phase 2 · Human Papilloma Virus (HPV)

Full Press Release Details

National recognition comes as Daré Bioscience advances a multi-product women’s health strategy across commercialization, clinical development and first-in-category innovation SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company

Frequently Asked Questions

Who is Sabrina Martucci Johnson?

Sabrina Martucci Johnson is the CEO of Daré Bioscience.

What recognition did Daré Bioscience receive?

Daré Bioscience's CEO was named to Forbes' 2026 '50 Over 50: Innovation' list.

What is Daré Bioscience focused on?

Daré Bioscience focuses on women's health, commercialization, and clinical development.

What does the Forbes list celebrate?

The Forbes '50 Over 50' list celebrates innovative leaders over the age of 50.

ShareAdd on Google
Tags: DARE Viatris Investor Conferences Healthcare Daré Bioscience women's health Forbes 50 Over 50 Sabrina Martucci Johnson biotech
Last updated: Aug 18, 2026

Biotech snapshot

Cash runway
$13M liquidity · $1M/mo burn
~13 mo
Low dilution risk
Lead asset
Lopinavir/ ritonavirPhase 2
Human Papilloma Virus (HPV) →